MedTrace Logo

A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

NCT05970432 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2023-08-01

No results posted yet for this study

Summary

This phase II clinical trials is multicenter, randomized, double-blind, placebo-controlled to assess the effectiveness and safety of TQH2722 injection in the treatment of subjects with moderate to severe atopic dermatitis.

Conditions

Interventions

DRUG

TQH2722 injection 300mg-150mg

TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.

DRUG

TQH2722 injection 600mg-300mg

TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.

DRUG

TQH2722 injection 900mg-450mg

TQH2722 injection is a fully human monoclonal antibody that thereby interfering with the signal cascade.

DRUG

TQH2722 injection matching Placebo

Placebo without active substance.

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-19
Primary Completion
2024-03-31
Completion
2024-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05970432 on ClinicalTrials.gov